text:
Complex Integrated Multi-Component Projects in Aging Research (U19)
U19 Research Program – Cooperative Agreements
NOT-OD-18-009 - Reminder: FORMS-E Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2018.
September 20, 2017 - Updates to Active Funding Opportunity Announcements to Prepare for Policy Changes Impacting Due Dates On or After January 25, 2018. See NOT-OD-17-114.
November 1, 2017 - This PAR has been reissued as PAR-18-296 for due dates on or after January 25, 2018.
May 10, 2017 - New NIH "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates On or After January 25, 2018. See NOT-OD-17-062.
June 30, 2016 - Notice of Correction for PAR-16-143. See Notice NOT-AG-16-032.
NOT-OD-16-004 - NIH & AHRQ Announce Upcoming Changes to Policies, Instructions and Forms for 2016 Grant Applications (November 18, 2015)
PAR-16-143
Companion Funding Opportunity
Funding Opportunity Purpose
This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions.
Letter of Intent Due Date(s)
30 days prior to the application due date
Any due dates on or after Jan 25, 2018 must use reissued FOA.
Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Standard AIDS dates apply or Month(s) Day(s), Year(s), by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
Earliest Start Date
New Date January 24, 2018 per reissuance of FOA (Original Expiration Date: September 8, 2019)
** ELECTRONIC APPLICATION SUBMISSION REQUIRED**
NIH's new Application Submission System & Interface for Submission Tracking (ASSIST) is available for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. Applications to this FOA must be submitted electronically; paper applications will not be accepted. ASSIST replaces the Grants.gov downloadable forms currently used with most NIH opportunities and provides many features to enable electronic multi-project application submission and improve data quality, including: pre-population of organization and PD/PI data, pre-submission validation of many agency business rules and the generation of data summaries in the application image used for review.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts) and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
Aging research frequently entails a multidisciplinary effort, drawing on the expertise and resources of multiple individuals, institutions, and communities. Some studies require large-scale approaches requiring coordination of multiple components or across multiple sites in order to leverage a wide range of necessary resources and expertise. However, the scale and complexity of such projects are often unsuitable for traditional NIH mechanisms (e.g., R01), and instead, require more specialized mechanisms to successfully coordinate their multiple interacting components and allow for adequate presentation of the breadth and complexity of the proposed project to peer reviewers.
This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions. Resources and study expertise will be tightly coordinated across multiple sites or cores, such as:
One or more coordinating centers
Clinical or study sites
Specialized cores, such as for data management and analysis, measurement and phenotyping, animal models, etc.
Examples of the kinds of studies supported under this announcement include, but are not limited to, one or a combination of the following:
Large-scale longitudinal observational studies of diseases or conditions that are common in aging populations involving integration of multiple clinical outcomes with molecular, genetic, or other mechanistic data.
Large-scale, multi-site intervention studies in human subjects and/or animal models for aging-related conditions involving multiple endpoints to assess efficacy or effectiveness and to elucidate mechanisms.
Translation of basic science findings into pre-clinical or clinical studies, or of clinical findings into practice or community settings, for prevention, diagnosis, or treatment of aging-related conditions, requiring coordination of broad multidisciplinary expertise across multiple settings.
The structure and approach of proposed projects will vary depending on the hypotheses under study; however, it is expected that all projects will focus on an overarching scientific question that integrates all study components into a unified whole
Applicants are strongly encouraged to contact NIA Scientific/Research staff at least 6 weeks in advance of the anticipated application due date. This will help applicants ensure their prospective projects are aligned with NIA program priorities and consistent with administrative and budgetary policies.
Successful projects are expected to have a sound scientific rationale based on adequate preliminary data; however, investigators may propose preliminary activities where necessary to refine methods or protocols, or to test effectiveness of study component integration prior to full-scale study implementation.
In addition, investigators may choose to establish standing committees among study personnel for specialized cross-project functions such as a steering committee, data access and publications oversight, training of study personnel, etc. Applicants may also propose an external advisory committee to regularly review the progress of the multi-component project and provide non-binding recommendations for its activities.
Studies involving human interventions should comply with NIH's and NIA's policies on human intervention studies, including development of a data and safety monitoring plan. Specific individuals who may constitute a data and safety monitoring board (DSMB) should not be named in the application.
Research infrastructure development necessary to achieve the scientific aims of the planned study may be proposed.
See Section VIII. Other Information for award authorities and regulations.
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
Clinical Trial?
Clinical Trials Not Allowed for due dates on or after January 25, 2018: Only accepting applications that do not propose clinical trials
Need help determining whether you are doing a clinical trial?
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Application budgets are not limited but need to reflect the actual needs of the proposed project.
The maximum project period is 5 years.
Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Applicant Organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
System for Award Management (SAM) (formerly CCR) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).
Applicants can access the SF424 (R&R) application package associated with this funding opportunity using the "Apply for Grant Electronically" button in this FOA or following the directions provided at Grants.gov.
Most applicants will use NIH's ASSIST system to prepare and submit applications through Grants.gov to NIH. Applications prepared and submitted using applicant systems capable of submitting electronic multi-project applications to Grants.gov will also be accepted.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
Descriptive title of proposed activity
Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
Names of other key personnel
Participating institution(s)
Number and title of this funding opportunity
The letter of intent should be sent to:
Ramesh Vemuri, PhD
Email: vemurir@mail.nih.gov
Component Types Available in ASSIST
Research Strategy/Program Plan Page Limits
Admin Core
Additional page limits described in the SF424 Application Guide and the Table of Page Limits must be followed.
Instructions for the Submission of Multi-Component Applications
The following section supplements the instructions found in the SF424 (R&R) Application Guide, and should be used for preparing a multi-component application.
Revision applications must include an Overall component and the components that are affected by the revision. Therefore, the component requirements listed below may not apply to the revision application.
The application should consist of the following components:
Overall: required (1)
Administrative Core: required (1)
Cores: optional (0-9)
Projects: required (1-9)
Overall Component
When preparing your application in ASSIST, use Component Type 'Overall'.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
SF424 (R&R) Cover (Overall)
Complete entire form.
PHS 398 Cover Page Supplement (Overall)
Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.
Research & Related Other Project Information (Overall)
Follow standard instructions.
Project/Performance Site Location(s) (Overall)
Enter primary site only.
A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.
Research & Related Senior/Key Person Profile (Overall)
Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.
A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.
Budget (Overall)
The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.
A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.
PHS 398 Research Plan (Overall)
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is required in the Overall component.
Specific Aims: Describe the overall scientific objective of the proposed multi-component project, the individual aims of the project, and how the individual components contribute to these aims and the overall objective
Research Strategy:
Significance. Focusing on the project as a whole address (i) the importance of the problem or critical barrier to the field that the proposed project addresses, (ii) how the proposed project will improve scientific knowledge, technical capability, and/or clinical practice in one or more broad fields, (iii) how the concepts, methods, technologies, treatments, services, or preventive interventions that drive this field will be changed if the proposed aims are achieved. Describe the preliminary data on which the project is based.
Renewals. In addition to the above, identify and justify any changes in research emphasis and funds requested. If the structure of individual projects and cores has changed, identify the cores and projects consecutively (numbers for projects and letters for cores) according to how they are arranged in the current application. Show the correspondence to the prior structure.
Resubmissions. If the structure of projects and cores has changed, identify the cores and projects consecutively (numbers for projects and letters for cores) according to how they are arranged in the current application. Show the correspondence to the prior structure.
Innovation. Considering the project as a whole, show how the proposed research seeks to shift current research or clinical practice paradigms through use of novel concepts, approaches, methodologies, instrumentation, or interventions. Are these concepts, approaches, methodologies, instrumentation or interventions novel to the research field or novel in a broad sense? Does the proposed work refine, or improve, or apply in a new way, the concepts, approaches, methodologies, instrumentation or interventions proposed?
Approach. Include the major approaches and studies involved in the application showing how the approaches of cores and/or projects are tightly integrated with each other. Describe the mechanisms that will ensure the coherence of the project and maintain a multidisciplinary focus.
Renewals. Describe progress from the prior period of support that is of particular significance to the project as a whole. If the current submission omits individual projects or cores that were active in the prior funding period, describe their progress and explain why they are omitted. Identify and justify any substantive differences in approaches from the prior funding period.
Protection of Human Subjects: Follow instructions in the SF424 (R&R) Application Guide and also provide a data safety monitory plan (DSMP) for any human intervention study per NIA policies for human intervention studies. Plans for protection of human subjects that are specific to particular cores or projects should be described in those respective components of the application.
Letters of Support: Provide any letters of support specific to the Overall component.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
PHS Assignment Request Form (Overall)
All instructions in the SF424 (R&R) Application Guide must be followed.
When preparing your application in ASSIST, use Component Type 'Admin Core.'
SF424 (R&R) Cover (Administrative Core)
Complete only the following fields:
Type of Applicant (optional)
Descriptive Title of Applicant's Project
Proposed Project Start/Ending Dates
PHS 398 Cover Page Supplement (Administrative Core)
Enter Human Embryonic Stem Cells in each relevant component.
Research & Related Other Project Information (Administrative Core)
Human Subjects: Answer only the 'Are Human Subjects Involved?' and 'Is the Project Exempt from Federal regulations?' questions.
Vertebrate Animals: Answer only the 'Are Vertebrate Animals Used?' question.
Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
Project /Performance Site Location(s) (Administrative Core)
List all performance sites that apply to the specific component.
Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
Research & Related Senior/Key Person Profile (Administrative Core)
In the Project Director/Principal Investigator section of the form, use Project Role of 'Other' with Category of 'Core Lead' and provide a valid eRA Commons ID in the Credential field.
In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
Budget (Administrative Core)
Budget forms appropriate for the specific component will be included in the application package.
Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
PHS 398 Research Plan (Administrative Core)
Introduction to Application: For Resubmission and Revision applications, an Introduction to Application is allowed for each component.
Specific Aims: The Administrative Core provides overall leadership to the program project and the aims of the core should show the elements by which leadership and integration will be achieved. If proposing a new external advisory board do not list proposed members in the application. Instead list intended areas of expertise
Significance. Describe how the activities of the administrative core will implement the overall vision of the program project as an integrated investigation of a scientific field or problem in aging.
Approach. Describe how the several elements proposed in the administrative core will be operationalized to achieve transparent communication across projects and cores, cross-project collaboration, and common objectives for the project as a whole. Elements should include, but not be limited to, means for internal quality control of research; management of day-to-day project activities, management of contractual agreements, resolution of disputes, allocation of funds, and plans for joint dissemination of study results. Function and intended areas of expertise of an external advisory board, if proposed, should be described here.
Letters of Support: If a renewal project previously had an external advisory board then letters of support should be provided from members continuing in the next proposed period. If this is a new application or a renewal application with new external advisory board members, do not provide letters of support from proposed new members
PHS Inclusion Enrollment Report (Administrative Core)
Form only available in FORMS-D application packages for use with due dates on or before January 24, 2018.
When conducting clinical research, follow all instructions for completing PHS Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.
Optional Core
When preparing your application in ASSIST, use Component Type 'Core.'
SF424 (R&R) Cover (Optional Core)
PHS 398 Cover Page Supplement (Optional Core)
Research & Related Other Project Information (Optional Core)
Project /Performance Site Location(s) (Optional Core)
Research & Related Senior/Key Person Profile (Optional Core)
Budget (Optional Core)
PHS 398 Research Plan (Optional Core)
Specific Aims: Identify which projects the Core will assist and the role of the Core in the overall project.
Organize the Research Strategy into sections on a. Significance, and b. Approach. Innovation will be considered in relation to Approach and Significance.
Protection of Human Subjects: Follow instructions in the SF424 (R&R) Application Guide and also provide a data safety monitory plan (DSMP) for any human intervention study per NIA policies for human intervention studies.
Letters of Support: Provide any letters of support that are specific to the relevant core.
PHS Inclusion Enrollment Report (Optional Core)
When conducting clinical research, follow all instructions for completing Cumulative Inclusion Enrollment Report as described in the SF424 (R&R) Application Guide.
When preparing your application in ASSIST, use Component Type 'Project.'
SF424 (R&R) Cover (Project)
PHS 398 Cover Page Supplement (Project)
Research & Related Other Project Information (Project)
Project /Performance Site Location(s) (Project)
Research & Related Senior/Key Person Profile (Project)
In the Project Director/Principal Investigator section of the form, use Project Role of 'Other' with Category of 'Project Lead' and provide a valid eRA Commons ID in the Credential field.
Budget (Project)
PHS 398 Research Plan (Project)
Specific Aims: Describe the aims of the project in relation to the goals of the overall project.
The Research Strategy should be organized into sections on Significance, Innovation and Approach.
The Significance section should include discussion of how this project relates to the goals of the overall project and the preliminary data on which the project is based. If the same study will be conducted across multiple sites, such as clinical or study sites using the same protocol, describe the study once in this section and indicate the sites where the protocol will be carried out.
Letters of Support: Provide any letters of support that are specific to this project.
PHS 398 Inclusion Enrollment Report (Project)
3. Unique Entity Identifier and System for Award Management (SAM)
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH's electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
For information on how your application will be automatically assembled for review and funding consideration after submission go to: https://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.
All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization's profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.
Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.
Applicants are required to follow our Post Submission Application Materials policy.
Overall Impact - Overall
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Scored Review Criteria - Overall
Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Is the preliminary data adequate to justify the project?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?
Additional Review Criteria - Overall
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Additional Review Considerations - Overall
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genomic Data Sharing Plan .
Authentication of Key Biological and/or Chemical Resources
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Scored Review Criteria - Administrative Core
Reviewers will consider each of the review criteria below in the determination of scientific merit, and provide an adjectival rating of high, moderate, or low enthusiasm. Reviewers will consider each of the four criteria below in the determination of scientific and technical merit. As cores are generally resources to enable or to advance research, "Innovation" is not considered routinely as a review criterion for these cores. Innovative cores may be valuable and that value will be assessed under Significance or Approach as appropriate.
Does the proposed core address the needs of the multi-component project that it will administer? Is the scope of activities proposed for the core appropriate to meet those needs? Will successful completion of the aims bring unique advantages or capabilities to the multi-component project? How well do the described activities integrate the separate elements of the project and provide overall direction? How well do proposed dissemination activities, if proposed, reflect an integrated project?
Are the Core Leads and other personnel well suited to their roles in the core? Do they have appropriate experience and training, and have they demonstrated experience and an ongoing record of accomplishments in managing aging research? Do the investigators demonstrate significant experience with coordinating collaborative research? If the core is collaborative do the investigators have complementary and integrated expertise and skills; are their leadership approach, governance, plans for conflict resolution, and organizational structure appropriate for the core? Does the applicant have experience overseeing selection and management of subawards, if needed? How well do the administrative, management, and leadership capabilities of the core leader(s) provide oversight and direction to the management activities of the core?
Are the operational plan and organizational structure well justified? Is the core adequate to support and encourage optimal interactions among the overall program team? How appropriate are the plans for internal quality control of research; management of day-to-day program activities; management of contractual agreements; resolution of disputes; and allocation of funds? Are the overall strategy, operational plan, and organizational structure well-reasoned and appropriate to accomplish the goals of the multi-component project that the core will serve? Will the investigators promote strategies to ensure a robust and unbiased scientific approach across the multi-component project, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented?
Will the institutional environment in which the core will operate contribute to the probability of success in facilitating the multi-component project it serves? Are the institutional support, equipment and other physical resources available to the investigators adequate for the core proposed? Will the core benefit from unique features of the institutional environment, infrastructure, or personnel? Are resources available within the scientific environment to support electronic information handling?
Scored Review Criteria - Optional Core
Does the core address an important problem or a critical barrier to progress in the field? If the aims of the core are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? What is the value of the core to the overall project and to particular projects?
Are the Core Leads, collaborators, and other researchers well suited to the core? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the core is collaborative, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the core? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the core involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the core proposed? Will the core benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? How well does the environment enhance integration of cores and projects? How well does it facilitate interactions among cores and projects?
Additional Review Criteria - Administrative and Optional Cores
As applicable for the core proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an adjectival enthusiasm rating, but will not give separate ratings for these items.
When the proposed core involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Additional Review Considerations - Administrative and Optional Cores
As applicable for the core proposed, reviewers will consider each of the following items, but will not give ratings for these items, and should not consider them in providing an overall impact score.
Scored Review Criteria - Individual Projects
Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Are the Project Lead, collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Additional Review Criteria - Individual Projects
Additional Review Considerations - Individual Projects
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by the National Institute on Aging in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council on Aging. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person's race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator's scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.
For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.
The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75, and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
coordinating the Research Project;
retaining primary responsibility for the planning, directing, and executing the proposed scientific activities;
ensuring that all projects involving human or animal subjects have the appropriate clearances (e.g., IRB, FWA, IACUC, human subject's research training, and other required documentation) prior to implementation;
submitting yearly progress reports for the Project; and
keeping the NIA Program Official and NIA Project Scientist apprised of any potential impediments to execution of the goals of the Project; and
Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.
NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
The role of the NIA/NIH Project Scientist in the cooperative agreement is to support and encourage the recipient's activities by substantial involvement as partners and facilitators in the process without assuming responsibilities that remain with the PD(s)/PI(s).
The NIA Project Scientist will monitor the progress of the Research Project, help coordinate research approaches, and contribute to the shaping of research projects or approaches as warranted. The NIA Project Scientist will support and facilitate this process but will not direct it.
The NIA Project Scientist will retain the option to recommend the withholding or reduction of support from any cooperative agreement that substantially fails to achieve its goals according to the milestones agreed to at the time of the award or fails to comply with the Terms and Conditions of the award.
Additionally, an agency program official or IC program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.
Areas of Joint Responsibility include:
The NIA Project Scientist will coordinate with the PD(s)/PI(s) to facilitate the achievement of program goals.
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.
When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
eRA Service Desk (Questions regarding ASSIST, eRA Commons registration, submitting and tracking an application, documenting system problems that threaten submission by the due date, post submission issues)
Finding Help Online: https://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
Grants.gov Customer Support (Questions regarding Grants.gov registration and submission, downloading forms and application packages)
Contact Center Telephone: 800-518-4726
Email: GrantsInfo@nih.gov (preferred method of contact)
Sanoj Suneja, PhD
Email: sunejas@mail.nih.gov
Ramesh Vemuri, PhD.
Robin Laney
Email: laneyr@mail.nih.gov
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.


text:
Charles Gounod
Charles-François Gounod (French pronunciation: [ʃaʁl fʁɑ̃swa ɡuno]; 17 June 1818 – 17 October or 18 October 1893) was a French composer, known for his Ave Maria as well as his operas Faust and Roméo et Juliette. Gounod was born in Paris, the son of a pianist mother and an artist father. His mother was his first piano teacher. Under her tutelage, Gounod first showed his musical talents. He entered the Paris Conservatoire, where he studied under Fromental Halévy and Pierre Zimmermann (he later married Zimmermann's daughter). In 1839, he won the Prix de Rome for his cantata Fernand. He was following his father; François-Louis Gounod (d. 1823) had won the second Prix de Rome in painting in 1783. During his stay of four years in Italy, Gounod studied the music of Palestrina and other sacred works of the sixteenth century; these he never ceased to cherish. Around 1846-47 he gave serious consideration to joining the priesthood, but he changed his mind before actually taking holy orders, and went back to composition. During that period, he was attached to the Church of Foreign Missions in Paris. In 1854, Gounod completed a Messe Solennelle, also known as the Saint Cecilia Mass.
Nosferatu the Vampyre
Werner Herzog's English version of F.W. Murnau's original film pays homage to many of the latter's memorable images with stunning recreations while creating a number of his own dreamy moments: the twilight hike of Bruno Ganz's Jonathan Harker through the fog-ringed Carpathian...
(1979) 107 min
German Horror
Werner Herzog's English version of F.W. Murnau's original film pays homage to...
Source: Charles Gounod on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under CC BY-SA

redpajama_set_name: RedPajamaCommonCrawl


INTRASKAN DC has packed the power and intelligence with latest dual Microprocessors to enhance the convenience of the clinician and patients. The sleek console with graphical LCD, displays exposure parameters, modes of operations and self diagnostic messages.
Designed for Safety and Precision, patented shielding technology for negligible leakage radiation and zero-drift scissor arm with various sizes to let you customize as per your requirement.
High frequency DC x-ray, 100KHz digital generator, offering good quality at a minimum dose.
The DC system significantly reduces harmful soft radiation, compared to the conventional AC x-ray.
The unique patented shielding technology results in virtually negligible leakage radiation.
X-ray tube current of minimum 4 to 8 mA in steps of 1mA and 50 to 70 KV in steps of 1KV.
Minimum exposure time of .04 to 4 sec in steps of 10 m sec.
Focal Spot size of 0.4 and 0.5 mm.
The x-ray unit have option for selecting exposure parameters for Adult & Child.
Certified by FDA, AERB, UL, CE & IEC.
Digital control for safety and reliability.


The design of the current generation of Neetra TV transmitters significantly contributes to the decrease of the overall cost of a broadcasting network. The new digital transmitters by Neetra provide excellent levels of efficiency, compact design and flexible configurations for digital TV broadcasting.
To satisfy the need of modern TV broadcsting, Neetra TV transmitters support the existing analog and digital standards, such as DVB-T, DVB-H, DVB-T2, ATSC, ATSC Mobile DTV, ISDB-T, ISDB-T and DTMB.
Made in Italy is our brand of quality.
Our TV broadcasting products are entirely designed, assembled and tested in Italy. The care for details, the continuous research for efficiency and the attention to innovation make of our transmitters the feather in our cap. Stress test, EMC, radio Safety performed in laboratory on every single device assure the best efficiency and reliability.
Not only respect for the basic environmental rules, but also special consideration for energy saving. These are some of the features of Neetra products. With Doerthy technology we can drastically cut energy cost, also thanks to the high efficiency of our amplifiers. This is an additional reason why our products comply to the requirements of many national and international tenders.
See our TV Broadcasting Equipment.


This statistic presents the three largest initial public offerings (IPOs) in United Kingdom (UK) in the fourth quarter of 2017. In that time EN + Group plc was valued highest through the process of IPO, at 1,119 million British pounds.
IPO stands for initial public offering. IPO is the process when the shares of a private company are sold to the public investors for the first time. Capital raised is the valuation of the company through IPO.


text:
En linguistique, le superessif est un cas locatif statique externe. Correspondant en hongrois au suffixe -n, il exprime le lieu sur lequel on est (ce qui équivaut en général à un adessif en finnois).
Le finnois connaît aussi un  cas superessif de suffixe -alla/-ällä qui ne s'utilise qu'avec un nombre limité de racines afin de produire des adverbes de lieu statique externe.

Cas grammatical

redpajama_set_name: RedPajamaWikipedia


text:
Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites
Y. T. Sung, Y. S. Kim, Y. K. Lee, W. N. Kim, H. S. Lee, J. Y. Sung, H. G. Yoon
Department of Chemical and Biological Engineering
Graduate School of management of technology
The effects of clay on the morphology of the poly(acrylonitrile-butadiene- styrene) (ABS)/polypropylene (PP) nanocomposites were investigated. From the studies of wide angle X-ray diffraction (WAXD) and transmission electron microscopy (TEM) analysis of the ABS/PP (70/30) nanocomposites with clay, it was observed that most of the clay existed in the ABS matrix because of the good affinity between the ABS and clay which contained benzyl group. From the studies of the scanning electron microscopy (SEM) analysis, the size of the PP droplet decreased with clay from 16.7 to 5.6 μm when the clay was added up to 4.0 phr. When the clay content was increased, the droplet of the dispersed phase (PP) was shown to elongated structure. The elongated structure could be explained by the decrease of the viscosity ratio of the PP and continuous phase (ABS) with clay, which corresponded to the increase of the viscosity of the continuous phase (ABS/clay). From the results of the SEM, TEM, and WAXD analysis, it is suggested that the increase of the viscosity of the continuous phase (ABS/clay) is mainly due to the location of clay in the ABS matrix.
Polymer Engineering and Science
https://doi.org/10.1002/pen.20868
10.1002/pen.20868
Dive into the research topics of 'Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites'. Together they form a unique fingerprint.
Butadiene Engineering & Materials Science 100%
Styrene Engineering & Materials Science 97%
Nanocomposites Engineering & Materials Science 91%
Polypropylenes Engineering & Materials Science 86%
Clay Engineering & Materials Science 84%
Poly(propylene) Chemical Compounds 72%
Nanocomposite Chemical Compounds 56%
Wide-Angle X-Ray Scattering Chemical Compounds 22%
Sung, Y. T., Kim, Y. S., Lee, Y. K., Kim, W. N., Lee, H. S., Sung, J. Y., & Yoon, H. G. (2007). Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites. Polymer Engineering and Science, 47(10), 1671-1677. https://doi.org/10.1002/pen.20868
Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites. / Sung, Y. T.; Kim, Y. S.; Lee, Y. K.; Kim, W. N.; Lee, H. S.; Sung, J. Y.; Yoon, H. G.
In: Polymer Engineering and Science, Vol. 47, No. 10, 10.2007, p. 1671-1677.
Sung, YT, Kim, YS, Lee, YK, Kim, WN, Lee, HS, Sung, JY & Yoon, HG 2007, 'Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites', Polymer Engineering and Science, vol. 47, no. 10, pp. 1671-1677. https://doi.org/10.1002/pen.20868
Sung YT, Kim YS, Lee YK, Kim WN, Lee HS, Sung JY et al. Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites. Polymer Engineering and Science. 2007 Oct;47(10):1671-1677. https://doi.org/10.1002/pen.20868
Sung, Y. T. ; Kim, Y. S. ; Lee, Y. K. ; Kim, W. N. ; Lee, H. S. ; Sung, J. Y. ; Yoon, H. G. / Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites. In: Polymer Engineering and Science. 2007 ; Vol. 47, No. 10. pp. 1671-1677.
@article{f9179f6b0a34453eb614714e1c697cc1,
title = "Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites",
abstract = "The effects of clay on the morphology of the poly(acrylonitrile-butadiene- styrene) (ABS)/polypropylene (PP) nanocomposites were investigated. From the studies of wide angle X-ray diffraction (WAXD) and transmission electron microscopy (TEM) analysis of the ABS/PP (70/30) nanocomposites with clay, it was observed that most of the clay existed in the ABS matrix because of the good affinity between the ABS and clay which contained benzyl group. From the studies of the scanning electron microscopy (SEM) analysis, the size of the PP droplet decreased with clay from 16.7 to 5.6 μm when the clay was added up to 4.0 phr. When the clay content was increased, the droplet of the dispersed phase (PP) was shown to elongated structure. The elongated structure could be explained by the decrease of the viscosity ratio of the PP and continuous phase (ABS) with clay, which corresponded to the increase of the viscosity of the continuous phase (ABS/clay). From the results of the SEM, TEM, and WAXD analysis, it is suggested that the increase of the viscosity of the continuous phase (ABS/clay) is mainly due to the location of clay in the ABS matrix.",
author = "Sung, {Y. T.} and Kim, {Y. S.} and Lee, {Y. K.} and Kim, {W. N.} and Lee, {H. S.} and Sung, {J. Y.} and Yoon, {H. G.}",
doi = "10.1002/pen.20868",
journal = "Polymer Engineering and Science",
T1 - Effects of clay on the morphology of poly(acrylonitrile-butadiene-styrene) and polypropylene nanocomposites
AU - Sung, Y. T.
AU - Kim, Y. S.
AU - Lee, Y. K.
AU - Kim, W. N.
AU - Lee, H. S.
AU - Sung, J. Y.
AU - Yoon, H. G.
N2 - The effects of clay on the morphology of the poly(acrylonitrile-butadiene- styrene) (ABS)/polypropylene (PP) nanocomposites were investigated. From the studies of wide angle X-ray diffraction (WAXD) and transmission electron microscopy (TEM) analysis of the ABS/PP (70/30) nanocomposites with clay, it was observed that most of the clay existed in the ABS matrix because of the good affinity between the ABS and clay which contained benzyl group. From the studies of the scanning electron microscopy (SEM) analysis, the size of the PP droplet decreased with clay from 16.7 to 5.6 μm when the clay was added up to 4.0 phr. When the clay content was increased, the droplet of the dispersed phase (PP) was shown to elongated structure. The elongated structure could be explained by the decrease of the viscosity ratio of the PP and continuous phase (ABS) with clay, which corresponded to the increase of the viscosity of the continuous phase (ABS/clay). From the results of the SEM, TEM, and WAXD analysis, it is suggested that the increase of the viscosity of the continuous phase (ABS/clay) is mainly due to the location of clay in the ABS matrix.
AB - The effects of clay on the morphology of the poly(acrylonitrile-butadiene- styrene) (ABS)/polypropylene (PP) nanocomposites were investigated. From the studies of wide angle X-ray diffraction (WAXD) and transmission electron microscopy (TEM) analysis of the ABS/PP (70/30) nanocomposites with clay, it was observed that most of the clay existed in the ABS matrix because of the good affinity between the ABS and clay which contained benzyl group. From the studies of the scanning electron microscopy (SEM) analysis, the size of the PP droplet decreased with clay from 16.7 to 5.6 μm when the clay was added up to 4.0 phr. When the clay content was increased, the droplet of the dispersed phase (PP) was shown to elongated structure. The elongated structure could be explained by the decrease of the viscosity ratio of the PP and continuous phase (ABS) with clay, which corresponded to the increase of the viscosity of the continuous phase (ABS/clay). From the results of the SEM, TEM, and WAXD analysis, it is suggested that the increase of the viscosity of the continuous phase (ABS/clay) is mainly due to the location of clay in the ABS matrix.
U2 - 10.1002/pen.20868
DO - 10.1002/pen.20868
JO - Polymer Engineering and Science
JF - Polymer Engineering and Science


text:
Płatków – dawna gromada, czyli najmniejsza jednostka podziału terytorialnego Polskiej Rzeczypospolitej Ludowej w latach 1954–1972.

Gromady, z gromadzkimi radami narodowymi (GRN) jako organami władzy najniższego stopnia na wsi, funkcjonowały od reformy reorganizującej administrację wiejską przeprowadzonej jesienią 1954 do momentu ich zniesienia z dniem 1 stycznia 1973, tym samym wypierając organizację gminną w latach 1954–1972.

Gromadę Płatków z siedzibą GRN w Płatkowie utworzono – jako jedną z 8759 gromad na obszarze Polski – w powiecie wołomińskim w woj. warszawskim, na mocy uchwały nr VI/10/23/54 WRN w Warszawie z dnia 5 października 1954. W skład jednostki weszły obszary dotychczasowych gromad Anastazew, Basinów, Kiciny, Płatków i Podgać ze zniesionej gminy Zabrodzie w tymże powiecie. Dla gromady ustalono 12 członków gromadzkiej rady narodowej.

31 grudnia 1961 gromadę zniesiono, włączając jej obszar do nowo utworzonej gromady Obrąb w tymże powiecie.

Przypisy

Plxatkozzxw


The tasks for every carpenter may largely vary from one day to another. One client could simply need a few cabinets installed, while another one would go for a complete kitchen renovation. No matter how complex the job, we are glad to handle any type of woodwork. All carpenters at Handyman Express are multi-skilled tradesmen with deep knowledge of all things wood. If you believe you've got what it takes to do such jobs yourself, you might end up frustrated with the poor results. For instance, you could soon find yourself looking for the right specialist to fix faulty wooden floors or doors that just don't shut. So, why not skip all the wasted time by calling us in the first place.
Uneven surfaces, loose fitting floorboards and wonky doors will soon become a memory if you get hold of the carpentry services Handyman Express delivers for both business clients and regular home owners. Our promise: an affordable alternative to DIY nightmares and a first-grade service everytime we come.


Duke Darlington and the Big Sandy Pioneers have a Six-Man quarterfinal showdown with the Bridger Scouts tonight in Brider. The winner will advance to the semifinals next week. Tonight's game kicks off at 7.
The Big Sandy Pioneers ran their way to a first-round victory in the Six-Man football playoffs last weekend, but tonight, on the road, they will be tested by one of the best teams in the state.


text:
Satirist, essayist, poet and cleric Jonathan Swift was born 30 November 1667. He is remembered for works such as Gulliver's Travels, A Modest Proposal, A Journal to Stella, Drapier's Letters, The Battle of the Books, An Argument Against Abolishing Christianity, and A Tale of a Tub. Swift's family had several interesting literary connections: His grandmother, Elizabeth (Dryden) Swift, was the niece of Sir Erasmus Dryden, grandfather of the poet John Dryden. The same grandmother's aunt, Katherine (Throckmorton) Dryden, was a first cousin of Elizabeth, wife of Sir Walter Raleigh. His great-great grandmother, Margaret (Godwin) Swift, was the sister of Francis Godwin, author of The Man in the Moone which influenced parts of Swift's Gulliver's Travels. His uncle, Thomas Swift, married a daughter of the poet and playwright Sir William Davenant, a godson of William Shakespeare. He is probably the foremost prose satirist in the English language, and is less well known for his poetry. Swift originally published all of his works under pseudonyms – such as Lemuel Gulliver, Isaac Bickerstaff, MB Drapier – or anonymously. He is also known for being a master of two styles of satire: the Horatian and Juvenalian styles.
In February 1702, Swift received his Doctor of Divinity degree from Trinity College, Dublin. He then traveled to England and returned to Ireland in October, accompanied by Esther Johnson and his friend Rebecca Dingley, another member of William Temple's household. During his visits to England in these years Swift published A Tale of a Tub and The Battle of the Books (1704) and began to gain a reputation as a writer. This led to close, lifelong friendships with Alexander Pope, John Gay, and John Arbuthnot, forming the core of the Martinus Scriblerus Club. Swift also went to London many times & was recruited by The Tory Party to support their cause as editor of The Examiner. In 1711, Swift published the political pamphlet "The Conduct of the Allies & became part of the inner circle of the Tory government, and often acted as mediator between Henry St John (Viscount Bolingbroke) the secretary of state for foreign affairs (1710–15) and Robert Harley (Earl of Oxford) lord treasurer and prime minister (1711–14).
After the death of Queen Anne in 1714 and accession of George I, the Tory leaders were tried for treason for conducting secret negotiations with France so Swift returned to Ireland, where he began to support of Irish causes, producing some of his most memorable works: Proposal for Universal Use of Irish Manufacture (1720), Drapier's Letters (1724), and A Modest Proposal (1729), earning him the status of an Irish patriot. He began writing Travels into Several Remote Nations of the World, in Four Parts, by Lemuel Gulliver, first a surgeon, and then a captain of several ships, better known as Gulliver's Travels.
In 1726 he visited London, staying with his old friends Alexander Pope, John Arbuthnot and John Gay, who helped him arrange for the anonymous publication of Gulliver's Travels in 1726. It was immediately successful and was translated into. French, German, and Dutch. Swift returned to England in 1727 but The visit was cut short when Swift received word that Esther Johnson was dying and he rushed back home to be with her. On 28 January 1728, Esther Johnson died. Sadly After this, Death became a frequent feature in Swift's life. In 1731 he wrote Verses on the Death of Dr. Swift. In 1738 Swift began to show signs of illness, and in 1742 he may have suffered a stroke, losing the ability to speak. Swift sadly passed away on 19 October 1745 (aged 77), and was buried in his own cathedral by Esther Johnson's side, in accordance with his wishes. The bulk of his fortune (twelve thousand pounds) was left to found a hospital for the mentally ill, which opened in 1757. There have also been many film Animation and Television adaptations made of of the novel. including the 1939 version, a Hallmark version starring Ted Danson as Lemuel Gulliver, and the most recent one starring Jack Black.
← Mark Twain
Oscar Wilde →


text:
// --------------------------------------------------------------------------------------------------------------------
// <copyright file="ExpandoExtensionsTest.cs" company="Kephas Software SRL">
//   Copyright (c) Kephas Software SRL. All rights reserved.
//   Licensed under the MIT license. See LICENSE file in the project root for full license information.
// </copyright>
// <summary>
//   Implements the expando extensions test class.
// </summary>
// --------------------------------------------------------------------------------------------------------------------

namespace Kephas.Core.Tests.Dynamic
{
    using System.Collections.Generic;
    using System.Linq;

    using Kephas.Dynamic;

    using NUnit.Framework;

    [TestFixture]
    public class ExpandoExtensionsTest
    {
        [Test]
        public void Merge_obj_in_null()
        {
            var expando = (IExpando)null;
            var result = expando.Merge("1234");

            Assert.IsNull(result);
        }

        [Test]
        public void Merge_obj_in_expando()
        {
            var expando = new Expando();
            var result = expando.Merge("1234");

            Assert.AreSame(result, expando);
            Assert.AreEqual(expando["Length"], 4);
        }

        [Test]
        public void Merge_readonly_obj_in_expando()
        {
            var expando = new ExpandoWithReadonlyProperties("gigi") { Age = 20 };
            var result = expando.Merge(new ExpandoWithReadonlyProperties("belogea") { Age = 30 });

            Assert.AreEqual("gigi", result.Name);
            Assert.AreEqual(30, result.Age);
        }

        [Test]
        public void Merge_expando_no_private()
        {
            var expando = new Expando { ["my"] = "name" };
            var result = expando.Merge(new Expando { ["_is"] = "belogea" });

            Assert.AreEqual("name", result["my"]);
            Assert.IsNull(result["_is"]);
        }

        [Test]
        public void Merge_dictionary_of_string_in_expando()
        {
            var expando = new Expando();
            var result = expando.Merge(new Dictionary<string, string> { { "hi", "there" }, { "how", "are" }, { "you", "today" } });

            Assert.AreSame(result, expando);
            Assert.AreEqual("there", expando["hi"]);
            Assert.AreEqual("are", expando["how"]);
            Assert.AreEqual("today", expando["you"]);
        }

        [Test]
        public void Merge_dictionary_of_string_in_expando_no_private()
        {
            var expando = new Expando();
            var result = expando.Merge(new Dictionary<string, string> { { "_hi", "there" }, { "how", "are" }, { "you", "today" } });

            Assert.AreSame(result, expando);
            Assert.IsNull(expando["_hi"]);
            Assert.AreEqual("are", expando["how"]);
            Assert.AreEqual("today", expando["you"]);
        }

        [Test]
        public void Merge_dictionary_of_int_in_expando()
        {
            var expando = new Expando();
            var result = expando.Merge(new Dictionary<string, int> { { "hi", 1 }, { "how", 2 }, { "you", 3 } });

            Assert.AreSame(result, expando);
            Assert.AreEqual(1, expando["hi"]);
            Assert.AreEqual(2, expando["how"]);
            Assert.AreEqual(3, expando["you"]);
        }

        [Test]
        public void Merge_list_of_key_value_pairs_in_expando()
        {
            var expando = new Expando();
            var result = expando.Merge(new Dictionary<string, int> { { "hi", 1 }, { "how", 2 }, { "you", 3 } }.ToList());

            Assert.AreSame(result, expando);
            Assert.AreEqual(1, expando["hi"]);
            Assert.AreEqual(2, expando["how"]);
            Assert.AreEqual(3, expando["you"]);
        }

        [Test]
        public void GetLaxValue_string()
        {
            var expando = new Expando { ["myWay"] = "Frank Sinatra" };
            var actual = expando.GetLaxValue<string>("MyWay");

            Assert.AreEqual("Frank Sinatra", actual);
        }

        [Test]
        public void GetLaxValue_long_as_string()
        {
            var expando = new Expando { ["costs"] = "120000" };
            var actual = expando.GetLaxValue<long>("Costs");

            Assert.AreEqual(120000L, actual);
        }

        public class ExpandoWithReadonlyProperties : Expando
        {
            public ExpandoWithReadonlyProperties(string name)
            {
                this.Name = name;
            }

            public string Name { get; }

            public int Age { get; set; }
        }
    }
}

redpajama_set_name: RedPajamaGithub


Clark Atlanta is a private university formed from the 1988 merger of historically black institutions Clark College (founded in 1869) and Atlanta University (founded in 1865). Programs are offered through the Schools of Arts and Sciences, Business Administration, Education, International Affairs and Development, Library and Information Science, and Social Work. The 113-acre campus is located one mile west of downtown Atlanta.


text:
Comic Book Movies / TV
'Silk' Live-Action Series in the Works at Sony Pictures TV
by Fran J. Ruiz · September 4, 2020
Live-action web-slinging is coming to TV…
Variety is reporting that Silk, one of the latest additions to Spider-Man's character roster, is getting a live-action TV series from Koren-American writer Lauren Moon (Good Trouble, Atypical), who is in talks to develop the show for Sony Pictures TV.
This bit of news follows a series of developments which are signaling an exponential growth of Sony's Spider-Man-less Spider-Man universe, which is a concept that still boggles my mind.
Silk first appeared in the first number of 2014's The Amazing Spider-Man (not the film). Like Peter Parker, Cindy Moon was bitten by a radioactive spider, which gave her a set of powers similar to Spider-Man's.
The character already made live-action appearances in 2017's Spider-Man: Homecoming and 2018's Avengers: Infinity War as a student of Parker's Midtown School of Science and Technology. Sony might not need to recast Cindy, as TV veteran Tiffany Espensen played the role. Of course, this depends on whether Sony's Marvel Universe actually has a connection to Marvel's MCU or not, which is still unclear despite Sony teasing a cameo from Michael Keaton's Vulture in next year's Morbius.
Phil Lord and Chris Miller are serving as executive producers under their Lord Miller production banner along with former Sony Pictures Entertainment head Amy Pascal. Sources also indicate that Amazon is in talks to acquire the project, along with other potential Marvel series based on characters controlled by Sony.
Fran J. Ruiz
Francisco J. Ruiz is that guy who has watched Jurassic Park a thousand times and loves Star Wars. His hunger for movies is only matched by his love for video games. He graduated in English Studies from the University of Malaga, in Spain. As he continues to write about what he enjoys (and doesn't), he's studying for a master's degree and working on becoming a teacher.
Tags: MarvelSilkSony Pictures Television
Next story Genndy Tartakovsky's Glorious 'Primal' Returns this Fall with Five New Episodes
Previous story Zack Snyder's 'Army of the Dead' Expands with a Prequel Film, Anime Series


A man goes out with his friends for the night. Before he leaves he tells his wife, "I promise I will be home by midnight."
Midnight comes and goes. He finally arrives home at about 3 AM. As he walks in he realizes the cuckoo clock is about to go off. As it begins to go off he has a flash of genius and decides to coo another 9 times. He sneaks in to bed satisfied with himself.
The next morning he wakes up and his wife has breakfast made. She doesn't seem to be mad. Satisfied with himself he asks her, "You sleep okay last night?"
She replies, "Yeah, but we need a cuckoo clock."
He asks her why and she tells him, "Last night it cooed 3 times. Then it yelled, 'Crap!' It cooed another 6 times and giggled a little bit. Finally it cooed 3 more times, farted, and tripped on the carpet."


Owner of a BCI, which was dropped off at a shelter. Also, just purchased an albino BCI (Aug. 1, 11). Owned a BP in my younger days. So happy to be back with snakes, and love my boas.
01:56 PM - Deicide tagged photoed in thread the 2 twenty year old hun running millionaires.
11:42 AM - weird_science04 mentioned photoed in post Re: Star got balls??? No way!!!
06:28 AM - photoed changed their status to ""
09:04 PM - photoed changed their status to "Loving thewarmer weather"
06:20 PM - photoed changed their status to "So sick of the snow"


But there was this unsettling in my heart. There was always something better to obtain, that was always just outside of my grasp. I remember one day finally realizing there might be something wrong with me as I stood on the cobblestone streets of Rome, planning my next trip and subconsciously packing my bags to go home. As always, I was fixated on the next big thing and never able to witness the miracle of the moment right in front of me.
In 2007, my dad was diagnosed with stage 4 lung cancer. Despite my best intentions, I only made the 3-hour drive home to see him once in the 10 months that he dealt with chemo and radiation, fighting for his life. It seemed like every minute of every day was accounted for weeks in advance, like a giant snowball that had just been pushed downhill and I didn't know how to stop it. It took his death, and all the guilt that I was of no comfort to him in those last few months for me to realize how selfish my lifestyle had become. Yes, I was providing jobs for people, and pouring my life into ministry… but encountering death like that shifted something in my soul. And I knew that I had never truly done anything for anyone else before. It had only ever been about my race. My life was whizzing by in a blur, spiraling out of control… and his death posed a critical question. What end was I racing towards?
I stepped down from ministry, sold my business and got pregnant, which finally forced me to "be still and know that He is God." That time in His presence… I haven't found anything on this earth quite like it. It was like, just being saturated in his love and acceptance put everything back in proper order. I wasn't as important as I thought I was. I wasn't as insignificant as I feared I might be. I was just His, and He was mine. And I started to understand that this moment, this day, this life was really His.
I am far from perfect. I still don't make enough room for His presence in my daily life… and now that I have a couple of littles underfoot, be assured, I am finding it harder than ever to live in-the-moment. But every time I do make some room and acknowledge His presence in my day it is far more worthwhile than I would have guessed. I am catching glimpses of his glory in the simplest of moments. Glory that I believe is in every second of every day… and I want to get to the point where I catch every single one.
Is your life too full and whizzing by too fast?
Are you missing irreplaceable moments?
Do you really want to get to the finish line of your life in such a hurry?
Or perhaps, could all of us nobodies catch a glimpse of Somebody worth slowing down for?
I am in the middle of my race… and I am stopping.
Because He has already proven to be the most magnificent prize that I ever could have hoped for.


2: Local educational trips MCS is special. Our small size makes it so easy to take children out of the classroom into the real world to expand their education. We go on so many, it's impossible to list them all but they include the Royal Albert Museum, Topsham Maritime Museum, Exeter Canal boat trip, Trusham Quarry, Killerton House, Castle Drogo, Devon Wildlife Trust, Paignton Zoo, Living Coast, the National Aquarium and so many more.
5: Links to local Universities We think it is important for children to get a glimpse of what life at University is like. We have strong links with both Exeter and Plymouth Universities, taking the children to many event at both, such as: Science and Technology weeks, Sports Stars events, career fairs, lectures and lots more. We get many of our alumni returning to school, so give short talks and Q&As about their experiences.
7: Drama Productions | The school has a least two concerts each term, where ALL the pupils get involved. Starting with the Harvest Festival, each term the Sisters of the Presence of St Mary invite us to use their private Chapel, St Michael's & all Angels for the Christmas service, Easter Concert, and our finale each year the big summer Drama performance.
9: Music We all know the wonderful benefits of learning an instrument. Here at MCS we can accommodate all musical aspirations with our wonderful peripatetic staff. Then twice a term, every term, children are encouraged to perform in front of an audience, either solo, duet or part of a group.
10: Charities The children are magnificent at getting behind a cause. We enter 4 or 5 teams each year in the Rotary Club 'Exmoor Challenge'. 200 teams take part raising funds for the Children's Hospice SW. MCS often raise over 3/4 of the total raised for the entire event. The school council select a charity each year for the school to support. We of course support 'Sports Relief', 'Children in Need' and many more.
11: School Pets Providing a link for the children to learn and care for animals, grow food and flowers we believe is important.
12: Sports Day This has more of a village fete atmosphere. Everybody takes part: parents, teachers & children. Lots of fun, lots of events. We do have winners, but the emphasis is on taking part. Friends of MCS sell cream teas, just a lovely day.
13: Swimming We are lucky to have Exeter University's St Luke's campus swimming pool a short walk away. We've run a weekly swimming club for decades, with a swimming gala each term + taking part in the Exeter Primary School Swimming Gala. The school is also a member of the RLSS & runs lifesaving and personal survival courses.
17: Interschool Sport We are part of 'Devon School Games' which see us take part in a number of sports tournaments throughout the year, covering a huge range of sports from Swimming, Orienteering, Golf, Rugby, Cricket, Mini Olympics and many many more. It's all about enthusing pupils to take part in sport. So much fun!
18: Mountain Biking We are blessed with the diverse landscapes on our doorstep. So we go out rain or shine: Dartmoor, Haldon Forest, Woodbury, Exmoor, Fingle Bridge & many many more places. Sport does not need to be on a playing field!
19: Horse Riding MCS links with the lovely stables in Chudleigh on the edge of Dartmoor, the children get a chance to go on a hack, lessons in the school, horse husbandry and tack maintenance as well as visit all the other farm animals.
22: Summer Camp Our activities are all about challenging our children. Little steps, new environments, building skills & confidence,all give our children a 'Can-Do' approach to life. Summer Camp is often the first time children have stayed away from home - lots of fun, building a thirst for more, yet close to home at Dawlish Warren.
25: PGL is an outdoor activity centre that we have been using for over a decade. Activities include abseiling, surfing, quad biking and a challenge course. The emphasis is on completing the challenges as part of a team. Every Summer Term we take the children to PGL in North Devon for the weekend. It is a hugely popular experience due to the fantastic PGL staff.
26: Exmoor Challenge | Organised by the Rotary Club of Exmoor, this is a huge event with 200+ teams of 4 children, all undertaking a challenging 16-mile route within a set time. For each minute early or late that they arrive at a checkpoint they lose a point. MCS typically enters 4 or 5 teams each year.
28: Ten Tors | The Ten Tors event is organised by the Army. Teams of 6 children 14yrs+ undertake the grueling 35, 45 or 55 mile routes unsupported. It's a unique opportunity for children to take on a real challenge by themselves. The event requires a huge amount of training & commitment by the children & culminates in one of their biggest achievements.
31: Silver DofE - Cycling The DofE is all about enthusing pupils to try something new, playing an instrument, volunteering for a charity, undertaking a new sport or completing an expedition for a purpose they choose.
32: Gold DofE - Canoeing The children have to plan & organise 4 Day Practice expeditions on the Thames & Wye, with an assessed expedition on the River Tarn, in southern France.
33: Assemblies Each morning we have a whole school assembly. Sometimes just a short 'thought for the day' with messages and a prayer, but we also get a wide range of speakers in. We celebrate a wide range of different faith special days, celebrate being British After each school trip or event we show a slide show or video. It's a great celebration of Magdalen Court School, St Leonards, Exeter, England and the wholeUK community.
37: We link with a French sailing school in Brittany: sailing, kayaking, windsurfing, beach games & lots more while staying in a magnificent 5* campsite on the most beautiful Brittany beaches. We visit local markets and try local delicacies like mussels & artichokes, cycle across the causeway to the adjoining islands & lots lots more.
38: Dry Ski & Snow Dome This turns a 1-week holiday into a term's activity. It's a chance to use skiing for your DofE award or your GCSE or your A level PE. It also means when you arrive in the mountains you are ready to go!
40: SKIING | I believe we are the only school in Exeter than runs an annual ski trip. This is the highlight of many pupils' experiences at MCS and a chance to experience a different culture, the special mountain environment and the camaraderie of taking part in a sport. We make it even more special by linking it with a dry ski course here in Exeter, then a few sessions at the slope in Plymouth and finally a day at the Snow Dome in London, before heading off for a week in the mountains. Magic!
45: FOMCS | Friends of Magdalen Court School run a number of events through the year, sometimes raising money for the school, often it is just a chance to socialise with the other parents and teachers. Events include a Summer BBQ/rounders match, Spitchwick picnic at the pool on the river Dart, Devon Coast to Coast Walk 110 miles (1 day a month), the muddy Rock Solid Challenge event, and the heroic Marines Assault course.
46: Speech & Prize Giving Day Each term we have a large speech day & prize giving ceremony with a guest speaker. This is a chance to recognise the achievements of our pupils through the year.
47: Visiting Speakers | We invite in a wide range of outside speakers eg: Gideons, Coast Guard, Police, British Explorers Society, Red Cross, our Alumni, parents to talk about their careers, Dartmoor Zoo etc.
48: MCS Accreditation We offer a huge range of qualifications children can work towards accreditation by MCS. We believe it's important to reward effort and achievement as pupils work towards larger goals.


text:
AR goggles make crime scene investigation a desk job
Technology 31 January 2012
Don't touch anything
(Image: Jeff J. Mitchell/Getty)
CRIME scene investigators could one day help solve murders without leaving the office. A pair of augmented reality glasses could allow local police to virtually tag objects in a crime scene, and build a clean record of the scene in 3D video before evidence is removed for processing.
The system, being developed by Oytun Akman and colleagues at the Delft University of Technology in the Netherlands, consists of a head-mounted display receiving 3D video from a pair of attached cameras controlled by a laptop carried in a backpack. This arrangement lets the wearer see their surroundings as normal while also allowing them to overlay virtual objects, which are placed using hand gestures.
A menu appears to float over the left hand when the wearer holds it in front of them. Moving the left hand back and forth selects from a variety of tools, while the right hand serves as a pointer to tag objects in the scene, like blood spatter or bullet holes. The system stores the markers as part of a 3D model of the scene, which investigators can use to help their investigation. It may also be admissible in court as evidence.
"The glasses allow the wearer to tag objects seen in a scene, like blood splatter or bullet holes"
If the person wearing the glasses requires assistance, they can contact someone back in the lab who can watch their video stream, speak to the wearer through a headset and place markers in the scene using a mouse and keyboard. This would also allow a police officer to take the first look around a crime scene.
Akman says that testers in a mock crime scene did not initially like being watched. "They felt intimidated or disturbed by having someone else behind their head," he says. "But then they got used to it and liked the idea."
Akman and his colleagues now plan to test the system in a real-world crime scene with the help of the Dutch police and will also investigate the possibility of using the glasses as a tool for training new crime scene investigators. They will present their work at the Computer Supported Cooperative Work conference in Bellevue, Washington, next month.
Dean Northfield, an imaging officer at the UK's West Yorkshire police, says the glasses could help police forces make the best use of their limited resources, but adds that investigators might resist changes to their current work methods. "It would need testing against what is being done now to actually see what the benefits are," he says.
Magazine issue 2849 , published 28 January 2012
Virtual trees sway in wind just like the real thing
Pinch-screen puts all your fingers in control


Show off your car and share some stories, enjoy a great breakfast!
Sponsored by Cameron's Coffee and Chocolates, home of the World's Best Coffee and Burrito combo…it will rev your engine.
Lots of Fun, Lots of Cars, Lots of Coffee. Come join us!


Morneau Law offers estate planning in NH, which will allow you to have the necessary documents in place should something happen to you or your loved ones. We will evaluate your needs and recommend the best estate planning package for you. Your estate planning attorney can also review your current Will, Durable Power of Attorney, Durable Power of Attorney for Health Care, Living Will or Trust documents. We can prepare each document independently should you not wish to have the complete package. It is recommended that you update your estate planning documents once a year or upon any life changing event such as divorce, death of a family member or birth of a child.
We take a holistic approach to working with seniors and their families from estate planning to long term care. You need a team of professionals that can address your legal, medical, financial, social and family concerns. Let us help create a plan for you and ensure you are connected to those individuals who can help you with each step.
Everyone should have a properly executed Will in order to ensure that your final wishes are respected. Having a Will allows you to protect the people you care about from having to go through a long, expensive court process to distribute your assets. If you do not have a Will in place, the government will decide how your assets are distributed.
A Revocable or Irrevocable trust is an invaluable estate planning tool which allows you to provide for your loved ones without the costly and complicated probate process. Additionally, Trusts help you to accomplish comprehensive asset management that benefits the people you care about most, but can be especially helpful during your lifetime should you become incapacitated. Trusts are also beneficial for complicated planning needs that involve minors and the need for guardianship. Many people assume trusts are only for people with large estates for tax avoidance purposes, but that is only one of the many reasons to employ a trust.
Having a Durable Power of Attorney for Financial Matters in place will allow a person of your choosing to manage your financial responsibilities. In the event that you become disabled or incapacitated, this document empowers your designated agent to step in and take care of your financial affairs. It is essential to understand how the Durable Power of Attorney works prior to executing a document of this significance. It is important to have these estate planning documents in place to protect your family from having to take emergency steps through the court system later.
Having a Durable Power of Attorney for Health Care in place will allow you to select a person of your choosing to make any and all health care decisions for you when you lack the capacity to make health care decisions for yourself. We often recommend having both a Durable Power of Attorney for Health Case and a Living Will in place as part of an estate plan.
A Living Will allows you to direct whether or not you wish life-sustaining treatment to be initialized when you are unable to speak for yourself under certain medical circumstances. Your Living Will also designates whether you want medically administered nutrition and hydration. By providing your wishes in advance, your family will not have to make these difficult decisions for you later.
Should you or a loved one be considering the necessity of nursing home care, one of the many important considerations will be how to cover the cost of such care. If you are not sure if you qualify for Medicaid, it is important to speak with a professional who can help you decide whether or not to pursue Medicaid for the purposes of long term nursing home care.
When you come in to meet with us we will help you determine whether or not you or your loved one would be eligible for Medicaid, and if so we will also guide you through the process of the application, requesting a resource assessment, assistance with the interview process, and if necessary we can help you through the appeal process.
Should you be in the unfortunate position of losing a loved one and need to deal with the complicated process of settling the estate we can help you to navigate the probate system. In the event of an individual's death certain protocols must be followed in a timely fashion, so do not hesitate to set up an appointment to meet with us as soon as possible.
Each estate plan is different. Where we excel is creative thinking, coming up with fresh ideas and solutions that will work best for you and your family.
Estate Lawyers Kate Morneau, Liz LaRochelle, and Sarah Paris are eager to help you. Call (603) 943-5647 or use our form to reach us now via email.
2. The second step will be a meeting. You'll walk away with an initial action plan.